A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

NCT06742892 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: HLX43 DOSE 1
DRUG: HLX43 DOSE 2
DRUG: HLX43 DOSE 3

Sponsor

Shanghai Henlius Biotech